Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02437617 · ClinicalTrials.gov registry record
Genomic Profiling Assay in Phase I
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 500
- Enrollment target
NCT02437617: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT02437617 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02437617 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
Study Summary
The goal of this research study is to collect and test tumor tissue from patients with advanced cancers that may be enrolled in Phase 1 studies or other treatments. Researchers will study if the results from genetic testing can help researchers determine which therapy may prove more beneficial for a patient in the future.
Primary Outcome
Response rate of each of the three cohorts (matched targeted therapy group, control group #1 and control group #2) calculated along with its 95% confidence interval. Response rate defined as proportion of participants who experience complete response (CR) or partial response (PR). Clinical response evaluated according to the RECIST 1.1.
Interventions
- PROCEDURE Tumor Tissue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2012-07-13 |
| Est. Completion | 2021-06-01 |
What the finished NCT02437617 record still lists
NCT02437617 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Tumor Tissue is the first listed.
NCT02437617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02437617 about?
NCT02437617 is a clinical study titled "Genomic Profiling Assay in Phase I". The goal of this research study is to collect and test tumor tissue from patients with advanced cancers that may be enrolled in Phase 1 studies or other treatments. Researchers will study if the results from genetic testing can help researchers determine which therapy may prove more beneficial for a...
What is the current status of trial NCT02437617?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2012-07-13. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT02437617?
The interventions under investigation include: Tumor Tissue (PROCEDURE).
Who is sponsoring clinical trial NCT02437617?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI